Walmart is set to join the Nasdaq-100 Index, replacing British pharmaceutical giant AstraZeneca, as part of an index rebalancing effective before the market opens on January 20, according to a statement released by Nasdaq. This move follows Walmart’s earlier announcement in November that it would shift its primary stock listing from the New York Stock Exchange (NYSE) to Nasdaq, marking a significant change for the world’s largest retailer after decades on the NYSE.
The inclusion of Walmart in the Nasdaq-100 Index underscores the growing appeal of Nasdaq as a listing venue for large, high-profile companies. The Nasdaq-100 Index tracks 100 of the most valuable non-financial companies listed on the Nasdaq exchange and includes global leaders such as Apple, Nvidia, Microsoft, and Amazon. In addition to the main index, Walmart will also be added to the Nasdaq-100 Equal Weighted Index and the Nasdaq-100 Ex-Tech Sector Index, further expanding its presence across Nasdaq’s flagship benchmarks.
Companies often decide to change listing venues when they believe another exchange offers better alignment with their investor base, advanced trading technology, enhanced services, or lower listing and compliance costs. In recent years, Nasdaq has positioned itself as an attractive platform not only for technology companies but also for major consumer, healthcare, and industrial firms seeking broader exposure and index inclusion.
Several companies that moved from the NYSE to Nasdaq in 2025 cited the growing prestige and visibility of the Nasdaq-100 Index as a key factor in their decision. Being part of the index can lead to increased demand from index-tracking funds and institutional investors, potentially boosting liquidity and long-term shareholder value.
For Walmart, the transition represents more than a symbolic shift. It aligns the retail giant with a group of globally influential companies and reflects its evolving business model, which increasingly integrates e-commerce, technology, and data-driven operations. Meanwhile, AstraZeneca’s removal highlights the competitive and dynamic nature of major stock indices, where changes in market capitalization and listings can quickly reshape index composition.


Sable Offshore Wins Key Court Battle Over California Oil Pipeline
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 



